BJDX

Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.

Wall Street analysts forecast BJDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BJDX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Bluejay Diagnostics Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Bluejay Diagnostics Inc. EPS for the last quarter amounts to -1.01 USD, decreased -86.97 % YoY.

Bluejay Diagnostics Inc (BJDX) has 7 emplpoyees as of December 15 2025.

Today BJDX has the market capitalization of 1.90M USD.